Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Nizoral
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Nizoral
|
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:contraindication |
liver disease
pregnancy breastfeeding concurrent use of certain medications |
| gptkbp:dosage_form |
oral tablet
|
| gptkbp:effective_date |
gptkb:1981
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:has_ability |
200 mg
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nizoral tablets
|
| gptkbp:indication |
systemic fungal infections
candidiasis histoplasmosis blastomycosis dermatophyte infections |
| gptkbp:ingredients |
gptkb:ketoconazole
|
| gptkbp:interacts_with |
gptkb:warfarin
antacids certain antidepressants |
| gptkbp:is_atype_of |
J02 A C01
|
| gptkbp:is_monitored_by |
liver function tests
|
| gptkbp:is_used_for |
fungal infections
|
| gptkbp:legal_issue |
prescription only
|
| gptkbp:lifespan |
2-3 hours
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:packaging |
blister pack
|
| gptkbp:pharmacokinetics |
absorbed in gastrointestinal tract
inhibits ergosterol synthesis |
| gptkbp:population |
take with food
do not crush or chew report any signs of liver problems complete full course of therapy consult doctor if symptoms worsen avoid alcohol during treatment |
| gptkbp:previous_name |
gptkb:ketoconazole
|
| gptkbp:requires |
gptkb:theorem
|
| gptkbp:side_effect |
dizziness
headache nausea abdominal pain liver toxicity |
| gptkbp:storage |
room temperature
|